Pd14-11 the Antitumor Effects of Intravesical Therapy Combined With Recombinant BCG and Pembrolizumab in Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (PD14)1 May 2024PD14-11 THE ANTITUMOR EFFECTS OF INTRAVESICAL THERAPY COMBINED WITH RECOMBINANT BCG AND PEMBROLIZUMAB IN BLADDER CANCER Jung Hoon Kim, Jong Hyun Tae, Se Young Choi, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, Joongwon Choi, Jin Wook Kim, Yong Seong Lee, and Chung Beum Wee Jung Hoon KimJung Hoon Kim , Jong Hyun TaeJong Hyun Tae , Se Young ChoiSe Young Choi , In Ho ChangIn Ho Chang , Tae-Hyoung KimTae-Hyoung Kim , Soon Chul MyungSoon Chul Myung , Joongwon ChoiJoongwon Choi , Jin Wook KimJin Wook Kim , Yong Seong LeeYong Seong Lee , and Chung Beum WeeChung Beum Wee View All Author Informationhttps://doi.org/10.1097/01.JU.0001009472.76470.8c.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The recombinant Bacillus Calmette-Guérin (rBCG) is genetically modified BCG to enhance therapeutic efficacy and safety in patients with bladder cancer. Pembrolizumab is a type of immune checkpoint inhibitors that is used to treat bladder cancer. We aimed to evaluate effectiveness of combination with rBCG and pembrolizumab in in vitro and in vivo models of bladder cancer. METHODS: We investigated antitumor effects of rBCG-dltA and pembrolizumab in bladder cancer on a chip model which was an organoid 3-dimensional cell culture tool. The orthotopic mouse model was used to evaluate an in vivo effect of the combination therapy. In order to overcome the error caused by differences between species, additional experiment was conducted suing mouse PD1 inhibitor instead of pembrolizumab. RESULTS: The T24, bladder cancer cell line, was declined independently when rBCG-dltA and pembrolizumab was treated in bladder cancer on a chip model. The migration of monocytes was also significantly higher than that of other groups. In the orthotopic bladder cancer model, it was confirmed that the combination group inhibits the growth of bladder cancer. In vivo studies using mouse PD1 inhibitor showed similar results to the previous studies. CONCLUSIONS: We demonstrated that the intravesical therapy of rBCG-dltA and pembrolizumab is effective in treating the bladder cancer. This study suggests that the combination with BCG and immune checkpoint inhibitor could be a novel strategy for treatment in patients with BCG-unresponsive bladder cancer. Download PPTDownload PPTDownload PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e357 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jung Hoon Kim More articles by this author Jong Hyun Tae More articles by this author Se Young Choi More articles by this author In Ho Chang More articles by this author Tae-Hyoung Kim More articles by this author Soon Chul Myung More articles by this author Joongwon Choi More articles by this author Jin Wook Kim More articles by this author Yong Seong Lee More articles by this author Chung Beum Wee More articles by this author Expand All Advertisement PDF downloadLoading ...